Spantran en es it fr

Spantran Brand names, Spantran Analogs

Spantran Brand Names Mixture

  • No information avaliable

Spantran Chemical_Formula

C20H23NS

Spantran RX_link

No information avaliable

Spantran fda sheet

Spantran msds (material safety sheet)

Spantran Synthesis Reference

No information avaliable

Spantran Molecular Weight

309.469 g/mol

Spantran Melting Point

< 25 oC

Spantran H2O Solubility

Soluble as HCl salt

Spantran State

Liquid

Spantran LogP

5.7

Spantran Dosage Forms

Tablets (oral, 1 mg)

Spantran Indication

Used for the symptomatic treatment of parkinsonism.

Spantran Pharmacology

Metixene is a tertiary antimuscarinic with actions similar to those of atropine; it also has antihistaminic and direct antispasmodic properties. It is used for the symptomatic treatment of parkinsonism, including the alleviation of the extrapyramidal syndrome induced by other drugs such as phenothiazines, but, like other antimuscarinics, it is of no value against tardive dyskinesias. Metixene has been discontinued.

Spantran Absorption

Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.

Spantran side effects and Toxicity

Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.

Spantran Patient Information

Spantran Organisms Affected

Humans and other mammals